07:47 AM EST, 11/24/2025 (MT Newswires) -- Invivyd ( IVVD ) said Monday it has nominated its VBY329 investigational antibody for the prevention of respiratory syncytial virus among neonates, infants, and children for preclinical development.
The company expects to present in vitro VBY329 data at a future medical congress.
Invivyd ( IVVD ) said it expects to advance VBY329 toward investigational new drug application readiness in H2 2026 for development in pediatric RSV prophylaxis.
The company's shares were up 1.2% in recent premarket activity.